Designing optimal allocations for cancer screening using queuing network models.


Journal

PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922

Informations de publication

Date de publication:
05 2022
Historique:
received: 01 10 2021
accepted: 07 05 2022
revised: 09 06 2022
pubmed: 28 5 2022
medline: 14 6 2022
entrez: 27 5 2022
Statut: epublish

Résumé

Cancer is one of the leading causes of death, but mortality can be reduced by detecting tumors earlier so that treatment is initiated at a less aggressive stage. The tradeoff between costs associated with screening and its benefit makes the decision of whom to screen and when a challenge. To enable comparisons across screening strategies for any cancer type, we demonstrate a mathematical modeling platform based on the theory of queuing networks designed for quantifying the benefits of screening strategies. Our methodology can be used to design optimal screening protocols and to estimate their benefits for specific patient populations. Our method is amenable to exact analysis, thus circumventing the need for simulations, and is capable of exactly quantifying outcomes given variability in the age of diagnosis, rate of progression, and screening sensitivity and intervention outcomes. We demonstrate the power of this methodology by applying it to data from the Surveillance, Epidemiology and End Results (SEER) program. Our approach estimates the benefits that various novel screening programs would confer to different patient populations, thus enabling us to formulate an optimal screening allocation and quantify its potential effects for any cancer type and intervention.

Identifiants

pubmed: 35622852
doi: 10.1371/journal.pcbi.1010179
pii: PCOMPBIOL-D-21-01778
pmc: PMC9182689
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1010179

Subventions

Organisme : NCI NIH HHS
ID : U54 CA193461
Pays : United States

Déclaration de conflit d'intérêts

I have read the journal’s policy and the authors of this manuscript have the following competing interests: F.M. is a co-founder and consultant of Harbinger Health and is a consultant for Red Cell Partners and Zephyr AI. No other conflicts to declare.

Références

BMJ. 1999 Jul 17;319(7203):155-8
pubmed: 10406748
Am J Pathol. 2019 Jan;189(1):22-35
pubmed: 30558719
PLoS One. 2020 Sep 25;15(9):e0237802
pubmed: 32976510
Gastroenterol Clin North Am. 2012 Mar;41(1):143-57
pubmed: 22341255
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Cancers (Basel). 2020 Dec 09;12(12):
pubmed: 33317202
BMJ. 2018 Sep 05;362:k3519
pubmed: 30185521
Lancet Oncol. 2020 Nov;21(11):1397-1399
pubmed: 33031732
Br J Cancer. 2013 Jun 11;108(11):2205-40
pubmed: 23744281
Pancreas. 2021 Mar 1;50(3):251-279
pubmed: 33835956
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
J Am Med Inform Assoc. 2014 Feb;21(e1):e129-35
pubmed: 24043318
Ann Intern Med. 2007 Apr 3;146(7):502-10
pubmed: 17404352
Nat Rev Cancer. 2017 Jul 25;17(8):475-488
pubmed: 28740119
Ann Surg. 2013 Jan;257(1):17-26
pubmed: 22895395
J Midlife Health. 2019 Jan-Mar;10(1):3-5
pubmed: 31001049
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Nat Rev Dis Primers. 2017 Jul 27;3:17048
pubmed: 28748917
Am J Surg. 2015 Sep;210(3):409-16
pubmed: 26003200
Nat Rev Dis Primers. 2016 Aug 25;2:16061
pubmed: 27558151
Curr Opin Genet Dev. 2017 Feb;42:14-21
pubmed: 28126649
Gastrointest Endosc. 2019 May;89(5):1017-1025.e12
pubmed: 30639539
World J Urol. 2018 Sep;36(9):1341-1353
pubmed: 29610964
Ann Intern Med. 2016 Feb 16;164(4):215-25
pubmed: 26756606
NPJ Precis Oncol. 2019 Jan 28;3:3
pubmed: 30701196
Gastrointest Endosc. 2018 Sep;88(3):413-426
pubmed: 29709526
Gastrointest Endosc. 2003 Jan;57(1):23-9
pubmed: 12518126
Semin Thorac Cardiovasc Surg. 2009 Summer;21(2):97-104
pubmed: 19822280
Health Care Manag Sci. 2012 Dec;15(4):293-309
pubmed: 22302420
Cancer Control. 2008 Oct;15(4):280-7
pubmed: 18813195
Clin Colorectal Cancer. 2016 Sep;15(3):e65-74
pubmed: 26792032
Sci Rep. 2018 Aug 24;8(1):12787
pubmed: 30143694
Science. 2020 Jul 3;369(6499):
pubmed: 32345712
N Engl J Med. 2010 Apr 29;362(17):1605-17
pubmed: 20427809
Health Rep. 2015 Dec;26(12):9-15
pubmed: 26676234
Nat Rev Clin Oncol. 2010 Mar;7(3):163-72
pubmed: 20101258
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
JCO Clin Cancer Inform. 2018 Dec;2:1-12
pubmed: 30652561
Nature. 2010 Oct 28;467(7319):1114-7
pubmed: 20981102

Auteurs

Justin Dean (J)

Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, United States of America.

Evan Goldberg (E)

Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Franziska Michor (F)

Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, United States of America.
Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.
The Ludwig Center at Harvard, Boston, Massachusetts, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH